Company record · BYSI · Pharmaceutical Preparations
BeyondSpring Inc.
BeyondSpring Inc.'s chief financial officer on the record is Na Li, effective July 1, 2026, per the filing record.
The record holds 1 verified CFO change for BeyondSpring Inc. from Form 8-K filings, filed June 4, 2026 and the CFO signature on its 10-K filed March 25, 2026.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Filled |
|---|---|
| Officer | Na Li |
| Title as printed | Chief Financial Officer |
| Basis | Latest move: appointment, 8-K filed June 4, 2026 |
Seat timeline
2Every verified record for this seat, newest first, dated as the filing states it.
2026-06-04Appointment
BeyondSpring Inc. appoints Na Li as CFOeffective July 1, 2026 · 8-K filed June 4, 2026 · sec.gov, Item 5.02
2026-03-2510-K signature
Lan Huang signed the annual report as Chief Executive Officer and Director (Principal Executive Officer and Principal Financial and Accounting Officer)
10-K filed March 25, 2026 · sec.gov
“/s/ Lan Huang Name: Lan Huang Title: Chief Executive Officer and Director (Principal Executive Officer and Principal Financial and Accounting Officer)”
Company
| Ticker | BYSI |
|---|---|
| SEC CIK | 0001677940 |
| Industry (SIC) | Pharmaceutical Preparations (2834) |
| Roster note | The DEF 14A filed 2026-09-03 does not name Lan Huang near a Chief Financial Officer title; check for a change. An 8-K with Item 5.02 was filed on 2026-06-04, after this 10-K; any CFO change it reports is tracked on the moves record. |
Same industry on the record
8Other companies the roster files under SIC “Pharmaceutical Preparations”.
Cadrenal Therapeutics, Inc.CVKD
Interim CFO: John P. Sharp · effective June 25, 2026
Petros Pharmaceuticals, Inc.PTPI
Departure disclosed · Robert Weinstein · no successor on the record yet
Actinium Pharmaceuticals, Inc.ATNM
CFO: Matt David, M.D. · effective October 14, 2026
Adial Pharmaceuticals, Inc.ADIL
Departure disclosed · Vinay Shah · no successor on the record yet
CalciMedica, Inc.CALC
Departure disclosed · Stephen Bardin · no successor on the record yet
Cue Biopharma, Inc.CUE
CFO: James Ahlers · effective July 30, 2026
Emergent BioSolutions Inc.EBS
Change disclosed, effective January 1, 2027 · incoming: Frank Vargo
Faeth Therapeutics, Inc.SNSE
CFO: Brian Stephenson · effective June 13, 2026
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.